Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry — Uwe Zeymer (2021) | RDL Network
Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry
Article 2021 en
Authors
UZ
Uwe Zeymer
AC
Andrew L. Clark
VB
Vivencio Barrios
Abstract
1 min read
In this large multinational HFrEF registry, patients receiving sacubitril/valsartan tended to be younger with lower LVEF and higher NYHA class. Fewer than half of the patients received triple HF therapy.
Aldo Maggioni, Andrew L. Clark, Vivencio Barrios, Thibaud Damy, Jarosław Dróżdż, Cândida Fonseca, Lars H. Lund, Stefanie Kalus, Philippe Ferber, Rizwan I. Hussain, C Koch, Uwe Zeymer
Uwe Zeymer, Andrew L. Clark, Vivencio Barrios, Thibaud Damy, Jarosław Dróżdż, Cândida Fonseca, Lars H. Lund, Gabriele Di Comite, Stephan Hupfer, Aldo Maggioni
Discussion(0)
No comments yet. Be the first to comment.